The Case for Chemotherapy only for Localized Hodgkin Lymphoma

Oncologist

Volumn 14, Issue 12, 2009, Pages 1225-1231

  Straus, David J ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Chemotherapy; Localized hodgkin lymphoma

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; NAVELBINE; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE; VINCRISTINE;

BRACHIAL PLEXUS INJURY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHILDHOOD CANCER; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HEART INFARCTION; HODGKIN DISEASE; HUMAN; HYPOTHYROIDISM; LUNG FIBROSIS; LUNG TOXICITY; MORBIDITY; MORTALITY; MULTIPLE CYCLE TREATMENT; MUSCLE ATROPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RESTRICTIVE CARDIOMYOPATHY; REVIEW; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HODGKIN DISEASE; HUMANS; TREATMENT OUTCOME;

EID: 75449097223     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0129     Document Type: Review

References (46)

1. Noordijk EM, Carde P, Dupouy N et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: Long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006;24:3128 -3135.
2. Engert A, Franklin J, Eich HT et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: Final results of the GHSG HD7 trial. J Clin Oncol 2007;25:3495-3502.
3. Horning SJ, Hoppe RT, Advani RH et al. A prospective trial of involved field radiation (IFRT)+chemotherapy compared to extended field (EFRT) radiation for favorable Hodgkin disease: Survival differences and implications of mature follow-up for current combined modality therapy. J Clin Oncol 2007;25(18 suppl):8014.
4. Longo DL, Russo A, Duffey PL et al. Treatment of advanced-stage massive mediastinal Hodgkin's disease: The case for combined modality treatment. J Clin Oncol 1991;9:227-235.
5. Behar RA, Horning SJ, Hoppe RT. Hodgkin's disease with bulky mediastinal involvement: Effective management with combined modality therapy. Int J Radiat Oncol Biol Phys 1993;25:771-776.
6. Savage KJ, Connors JM, Wilson D et al. FDG-PET guided consolidative radiotherapy in patients with advanced stage Hodgkin lymphoma with residual abnormalites on post chemtherapy CT scan. Blood 2007;110:213.
7. Brusamolino E, Baio A, Orlandi E et al. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: A single-institution 15-year follow-up. Clin Cancer Res 2006;12:6487- 6493.
8. Hodgson DC, Pintilie M, Gitterman L et al. Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol 2007;25:11-15.
9. Dores GM, Metayer C, Curtis RE et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease:Apopulation-based evaluation over 25 years. J Clin Oncol 2002;20:3484 -3494.
10. Green DM, Hyland A, Barcos MP et al. Second malignant neoplasms after treatment for Hodgkin's disease in childhood or adolescence. J Clin Oncol 2000;18:1492-1499.
11. Travis LB, Gospodarowicz M, Curtis RE et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002;94:182-192.
12. Aleman BM, van den Belt-Dusebout AW, Klokman WJ et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003;21:3431-3439.
13. Oeffinger KC, Mertens AC, Sklar CA et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355:1572-1582.
14. Hull MC, Morris CG, Pepine CJ et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA 2003;290:2831-2837.
15. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993;270:1949-1955.
16. Adams MJ, Lipsitz SR, Colan SD et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004;22:3139 -3148.
17. Aleman BM, van den Belt-Dusebout AW, De Bruin ML et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109:1878-1886.
18. Matasar MJ, McCallen LN, Reidel ER et al. Late mortality and morbidity of patients with Hodgkin lymphoma treated in adulthood [abstract 8547]. J Clin Oncol 2009;27(15 suppl):445s.
19. De Bruin ML, Sparidans J, van't VeerMBet al. Breast cancer risk in female survivors of Hodgkin's lymphoma: Lower risk after smaller radiation volumes. J Clin Oncol 2009;27:4239-4246.
20. Abratt RP, Morgan GW, Silvestri G et al. Pulmonary complications of radiation therapy. Clin Chest Med 2004;25:167-177.
21. Sieniawski M, Franklin J, Nogova L et al. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma. J Clin Oncol 2007;25:2000 -2005.
22. Straus DJ, Portlock CS, Qin J et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004;104:3483-3489.
23. Meyer RM, Gospodarowicz MK, Connors JM et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:4634-4642.
24. Eghbali H, Brice P, Creemers G-Y et al. Comparison of three radiation dose levels after EBVP regimen in favorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): Preliminary results of the EORTCGELA H9-F trial [abstract 814]. Blood 2005;106:240a.
25. Noordijk EM, Carde P, Mandard AM et al. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie. Ann Oncol 1994;5(suppl 2):107-112.
26. Rueda Domínguez A, Márquez A, Gumá J et al. Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: Results after 7 years of a prospective study. Ann Oncol 2004;15:1798 -1804.
27. Canellos G. Chemotherapy alone for localized non-bulky Hodgkin lymphoma. Blood 2008;112:2591.
28. Bonadonna G, Bonfante V, Viviani S et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Longterm results. J Clin Oncol 2004;22:2835-2841.
29. Martin WG, Ristow KM, Habermann TM et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005;23:7614 -7620.
30. Rueda A, Sevilla I, Gumà J et al. Secondary prophylactic G-CSF (filgrastim) administration in chemotherapy of stage I and II Hodgkin's lymphoma with ABVD. Leuk Lymphoma 2001;41:353-358.
31. Younes A, Fayad L, Romaguera J et al. Safety and efficacy of once-percycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer 2006;42:2976 -2981.
32. Nangalia J, Smith H, Wimperis JZ. Isolated neutropenia duringABVDchemotherapy for Hodgkin lymphoma does not require growth factor support. Leuk Lymphoma 2008;49:1530 -1536.
33. Evens AM, Cilley J, Ortiz T et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: Low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol 2007;137:545-552.
34. Wedgwood A, Younes A. Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin lymphoma. Clin Lymphoma Myeloma 2007;8(suppl 2):S63-S66.
35. Santoro A, Bredenfeld H, Devizzi L et al. Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study. J Clin Oncol 2000;18:2615-2619.
36. Zinzani PL, Bendandi M, Stefoni V et al. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica 2000;85: 926-929.
37. Bartlett NL, Niedzwiecki D, Johnson JL et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007;18:1071-1079.
38. Straus D LA, Juweid M, Kostakoglu L et al. Doxorubicin, vinblastine and gemcitabine (AVG), a novel regimen for the treatment of early stage Hodgkin lymphoma (HL): Results of CALGB 50203. Blood 2007;110:214.
39. Canellos GP, Duggan D, Johnson J et al. How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? J Clin Oncol 2004;22:1532-1533.
40. Weihrauch MR, Re D, Scheidhauer K et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001;98:2930 -2934.
41. Kostakoglu L, Goldsmith SJ, Leonard JP et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 2006;107:2678 -2687.
42. Hutchings M, Mikhaeel NG, Fields PA et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005;16:1160 -1168.
43. Hutchings M, Loft A, Hansen M et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107:52-59.
44. Gallamini A, Hutchings M, Rigacci L et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746-3752.
45. Radford J, O'Doherty M, Barrington S et al. Results of the 2nd planned interim analysis of the RAPID trial (involved field radiotherapy versus no further treatment) in patients with clinical stages 1A and 2A Hodgkin lymphoma and a 'negative' FDG-PET scan after 3 cycles ABVD. Blood 2008; 112:369.
46. Dann EJ, Bar-Shalom R, Tamir A et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007;109:905-909.